Literature DB >> 20795540

The role of OX40 (CD134) in T-cell memory generation.

Andrew D Weinberg1.   

Abstract

Memory T-cell generation is limited by activation-induced cell death during the effector T-cell stage. Cell surface proteins are known to transmit signals that either accentuate or limit T-cell death after activation. This chapter will focus on the TNF-receptor family member OX40, which is expressed on effector T cells and when engaged greatly enhances survival of T cells leading to increased memory T-cell generation. Targeting OX40 in vivo can alter the fate ofT-cell survival. Enhancing OX40 signaling during Ag priming through agonists increases memory T-cell development, while blocking OX40 signaling decreases the memory T-cell pool. These two opposing outcomes provide therapeutic tools for blocking inflammation in autoimmune conditions and enhancing immunity in hosts harboring cancer or chronic pathogens. OX40 agonists and antagonists are in the first stages of human clinical trials and their therapeutic potential will soon be realized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20795540      PMCID: PMC7123855          DOI: 10.1007/978-1-4419-6451-9_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  65 in total

1.  Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).

Authors:  S D Pippig; C Peña-Rossi; J Long; W R Godfrey; D J Fowell; S L Reiner; M L Birkeland; R M Locksley; A N Barclay; N Killeen
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  Lineage relationship and protective immunity of memory CD8 T cell subsets.

Authors:  E John Wherry; Volker Teichgräber; Todd C Becker; David Masopust; Susan M Kaech; Rustom Antia; Ulrich H von Andrian; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

Review 3.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

Authors:  Kazuo Sugamura; Naoto Ishii; Andrew D Weinberg
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

4.  Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells.

Authors:  Pejman Soroosh; Shouji Ine; Kazuo Sugamura; Naoto Ishii
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 5.  Induction and maintenance of anergy in mature T cells.

Authors:  M K Jenkins; D Mueller; R H Schwartz; S Carding; K Bottomley; M J Stadecker; K B Urdahl; S D Norton
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 6.  T cell memory.

Authors:  R W Dutton; L M Bradley; S L Swain
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

7.  A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes.

Authors:  P J Martin; J A Ledbetter; Y Morishita; C H June; P G Beatty; J A Hansen
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

8.  The effect of TCR V beta 8 peptide protection and therapy on T cell populations isolated from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis.

Authors:  A D Weinberg; B Celnik; M Vainiene; A C Buenafe; A A Vandenbark; H Offner
Journal:  J Neuroimmunol       Date:  1994-01       Impact factor: 3.478

9.  OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent.

Authors:  Rodney A Prell; Dean E Evans; Colin Thalhofer; Tom Shi; Castle Funatake; Andrew D Weinberg
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

10.  OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.

Authors:  Giorgia Gri; Elena Gallo; Emma Di Carlo; Piero Musiani; Mario P Colombo
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

View more
  5 in total

1.  Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.

Authors:  Tommaso Lorenzi; Rebecca H Chisholm; Matteo Melensi; Alexander Lorz; Marcello Delitala
Journal:  Immunology       Date:  2015-08-02       Impact factor: 7.397

Review 2.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

3.  Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.

Authors:  William H Kitchens; Ying Dong; David V Mathews; Cynthia P Breeden; Elizabeth Strobert; Maria E Fuentes; Christian P Larsen; Mandy L Ford; Andrew B Adams
Journal:  JCI Insight       Date:  2017-03-09

Review 4.  Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation.

Authors:  Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle
Journal:  Transplant Rev (Orlando)       Date:  2019-04-05       Impact factor: 3.943

5.  TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.

Authors:  Peixiang Lan; Yihui Fan; Yue Zhao; Xiaohua Lou; Howard P Monsour; Xiaolong Zhang; Yongwon Choi; Yaling Dou; Naoto Ishii; Rafik M Ghobrial; Xiang Xiao; Xian Chang Li
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.